Latest News

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

Source link

Related posts

Regenstrief investigator calls for medicare payment for team-based care for dementia


Routine HPV vaccination linked to dramatic reduction in cervical disease among young women


World Medical Radiation Shielding Market Analysis, Trends, and Forecasts Report 2019-2025 –


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy